Patents by Inventor Dariusz Wodka

Dariusz Wodka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
    Publication number: 20090054426
    Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.
    Type: Application
    Filed: August 21, 2008
    Publication date: February 26, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Yixian Chen, Jurgen Dinges, Karla Drescher, Peer Jacobson, Hwan-soo Jae, Ravi Kurukulasuriya, James T. Link, David J. Madar, Jyoti R. Patel, Marina A. Pliushchev, Jeffrey J. Rohde, Lynne E. Rueter, Qi Shuai, Bryan K. Sorensen, Jiahong Wang, Karsten M. Wicke, Martin Winn, Dariusz Wodka, Vince Yeh, Hong Yong
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7071182
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: July 4, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Patent number: 7049307
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: May 23, 2006
    Assignee: Abbott Laboratories
    Inventors: Andrew J. Souers, Christine A. Collins, Ju Gao, Andrew S. Judd, Philip R. Kym, Mathew M. Mulhern, Hing L. Sham, Dariusz Wodka
  • 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
    Patent number: 6989392
    Abstract: The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, which antagonize the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor and are useful for the prevention or treatment of eating disorders, weight gain and obesity.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: January 24, 2006
    Assignee: Abbott Laboratories
    Inventors: Christine A. Collins, Ju Gao, Philip R. Kym, Jared C. Lewis, Andrew J. Souers, Anil Vasudevan, Dariusz Wodka
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
    Publication number: 20050277647
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: April 29, 2005
    Publication date: December 15, 2005
    Inventors: James Link, Yixian Chen, Hwan-Soo Jae, Jyoti Patel, Marina Pliushchev, Jeffrey Rohde, Qi Shuai, Bryan Sorensen, Martin Winn, Dariusz Wodka, Hong Yong
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050277638
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: December 15, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
    Publication number: 20050245745
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: April 29, 2004
    Publication date: November 3, 2005
    Inventors: James Link, Marina Pliushchev, Jeffrey Rohde, Dariusz Wodka
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
    Publication number: 20050245534
    Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
    Type: Application
    Filed: October 14, 2004
    Publication date: November 3, 2005
    Inventors: James Link, Marina Pliushchev, Jeffrey Rohde, Dariusz Wodka, Jyoti Patel, Qi Shuai
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050209274
    Abstract: The present invention is directed to compounds of formula (I), which antagonize of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: February 25, 2005
    Publication date: September 22, 2005
    Inventors: John Lynch, Christine Collins, Jennifer Freeman, Ju Gao, Rajesh Iyengar, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Andrew Souers, Gang Zhao, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050187279
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 22, 2004
    Publication date: August 25, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone receptor
    Patent number: 6921821
    Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I: where m is zero or one, n is zero to two, Y is oxygen or —N(R9)—, R1, R2, R3, R4, R5, R9 and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: July 26, 2005
    Assignee: Abbott Laboratories
    Inventors: Christopher Blackburn, Su-Jen Lai, Jennifer L. Che, Martin P. Maguire, Michael A. Patane, Matthew J. LaMarche, Courtney A. Cullis, James Brown, Anil Vasudevan, Jennifer C. Freeman, Mathew M. Mulhern, John K. Lynch, Ju Gao, Dariusz Wodka, Andrew J. Souers, Rajesh Iyengar, Mary Katherin Verzal, Philip R. Kym
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137243
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Anil Vasudevan, Dariusz Wodka
  • Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
    Publication number: 20050137187
    Abstract: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
    Type: Application
    Filed: December 23, 2003
    Publication date: June 23, 2005
    Inventors: Andrew Souers, Christine Collins, Ju Gao, Andrew Judd, Philip Kym, Mathew Mulhern, Hing Sham, Dariusz Wodka
  • Antagonists of melanin concentrating hormone receptor
    Publication number: 20040106645
    Abstract: This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1).
    Type: Application
    Filed: June 11, 2003
    Publication date: June 3, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Su-Jen Lai, Jennifer L. Che, Martin P. Maguire, Michael A. Patane, Matthew J. LaMarche, Courtney A. Cullis, James Brown, Anil Vasudevan, Jennifer C. Freeman, Mathew M. Mulhern, John K. Lynch, Ju Gao, Dariusz Wodka, Andrew J. Souers, Rajesh Iyengar, Mary Katherin Verzal, Philip R. Kym
  • 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
    Publication number: 20040063756
    Abstract: The present invention is related to compounds of formula (I), 1
    Type: Application
    Filed: June 12, 2003
    Publication date: April 1, 2004
    Inventors: Christine A. Collins, Ju Gao, Philip R. Kym, Jared C. Lewis, Andrew J. Souers, Anil Vasudevan, Dariusz Wodka